 | 
| ||
| home > Torrent Pharma > news | |||
| Torrent Pharmaceuticals pacts deal with Dr. Reddys Laboratories Ltd.
Torrent Pharma, the Ahmedabad-based pharmaceuticals major, today announced that it has concluded an agreement with Dr. Reddy’s Laboratories Ltd. (DRL) for exclusive commercialization of two of Torrent Pharma’s brands in Russia, viz. Listril (Lisinopril) and Listril Plus (Lisinopril HCTZ) | |||
| 29 Nov 2006
: Torrent Pharma, the Ahmedabad-based pharmaceuticals major, today announced that it has concluded an agreement with Dr. Reddy’s Laboratories Ltd. (DRL) for exclusive commercialization of two of Torrent Pharma’s brands in Russia, viz. Listril (Lisinopril) and Listril Plus (Lisinopril HCTZ). Both Listril and Listril Plus are cardiovascular drugs used in the treatment of high blood pressure. The agreement offers the potential for immediate commercialization of these two brands as they have already been registered in Russia. While Torrent Pharma will own the registration and trademarks of both the brands, DRL will get exclusive marketing rights to them. The deal provides both the companies the advantage to strengthen their position in the cardiovascular segment in the Russian market. This is the second such agreement that Torrent Pharma has signed with Dr. Reddy’s for Russia. The first was for licensing and supplying the formulation of one of its blockbuster drug “Domstal O” (Domperidone + Omeprazole) in the Gastro Intestinal segment in July 2004. Torrent Pharma had licensed the dossier and marketing authorization for the formulation to DRL, which it will soon launch under the brand name Omez D in Ukraine and Kazakhstan, followed by Russia and Belarus. About Torrent Pharma: Torrent Pharma has a presence in over 50 countries with more than 1000 product registrations worldwide. 8 wholly-owned subsidiaries in international markets give it a strong presence in the major markets of Brazil, Germany, USA, Russia, Japan, Mexico and important Asian / African countries. The Company’s manufacturing facilities are complaint with the world’s best and most stringent certifications, including the US FDA, MHRA (UK), EU cGMP, WHO, etc. Torrent Pharma’s R&D Centre has one of the most advanced infrastructures for both basic and applied research. The Company has a long-term commitment for NCE research and its key areas of focus are Metabolic disorders (especially diabetes and its complications, obesity), Cardiovascular disorders and Cerebrovascular disorders. About Dr. Reddy’s Established in 1984, Dr. Reddy's Laboratories is an emerging global pharmaceutical company with proven research capabilities. The Company is vertically integrated with a presence across the pharmaceutical value chain. It produces finished dosage forms, active pharmaceutical ingredients and biotechnology products and markets them globally, with focus on India, US, Europe and Russia. The Company conducts research in the areas of diabetes, cardiovascular, anti-infectives, inflammation and cancer. |
|||
| | ||
| home > Torrent Pharma > news | |||
 |
|||
| |||